NCT05004077 (RADICAL) is a Phase 4 clinical trial of AMIODARONE in Atrial Fibrillation, sponsored by Kevin W Hatton, MD, PhD.

Who is sponsoring NCT05004077?

NCT05004077 is sponsored by Kevin W Hatton, MD, PhD.

What drugs are being tested in NCT05004077?

Interventions in NCT05004077: AMIODARONE.

What condition does NCT05004077 study?

NCT05004077 studies Atrial Fibrillation.

Is NCT05004077 still recruiting?

NCT05004077 is currently terminated. Last updated 18 November 2023.

Are results published for NCT05004077?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-11-18 · How we verify

NCT05004077: RADICAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Repeated Amiodarone Dosing In Cardiac surgicaL Procedures

Terminated Phase 4 Results posted Last updated 18 November 2023

What this trial tests

Phase 4 trial testing AMIODARONE in Atrial Fibrillation in 3 participants. Terminated before completion.

Timeline

2 November 2021

Primary endpoint
10 October 2022

10 October 2022

Quick facts

Lead sponsor	Kevin W Hatton, MD, PhD
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	2 November 2021
Primary completion	10 October 2022
Estimated completion	10 October 2022
Sites	1 location across United States

Drugs / interventions tested

AMIODARONE (AMIODARONE) — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Kevin W Hatton, MD, PhD

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-center, prospective, randomized, open-label trial of subjects who develop atrial fibrillation after non-emergent cardiac surgery at the University of Kentucky Chandler Medical Center (UKCMC). Patients will be randomized to receive either a conventional amiodarone dosing regimen (CDR) or a repeated amiodarone bolus dosing regimen (RBDR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05004077 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kevin W Hatton, MD, PhD
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05004077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing